Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06555848

CERAMENT G as Part of the Surgical Treatment of Osteomyelitis in a Single-Stage Procedure

The study is a prospective cohort study of subjects where CERAMENT G was used as part of the surgical treatment of osteomyelitis in a single stage procedure.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Bone Infection Unit, Nuffield Orthopaedic Centtre, Oxford University Hospitals, MHS

Oxford, OX37HE, United Kingdom

Location status: Recruiting

Location contact

Jamie Ferguson, MD

CONTACT

[email protected]

+447482491449

Jamie Ferguson, MD

PRINCIPAL_INVESTIGATOR

About this study

The study is a prospective cohort study of subjects where CERAMENT G was used as part of the surgical treatment of osteomyelitis in a single stage procedure.

The purpose of this post market prospective cohort study is to obtain longer-term clinical and radiographic data on the safety and effectiveness of CERAMENT G as part of the surgical treatment of Osteomyelitis in a single-stage procedure.

Detailed questions to be answered are:

  • What is the nature, severity, and frequency of incomplete new bone formation?
  • What is the nature, severity, and frequency of the risks of probable adverse events and serious adverse events associated with incomplete new bone formation, including pathologic fractures and reinfection?

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects meeting the following inclusion criteria are to be included in the analysis:

  • Patients receiving CERAMENT G subsequent to surgical excision of osteomyelitis, with Cierny-Mader classification grades III or IV, who require dead-space management of a bone defect following surgical debridement and excision of infection.
  • Symptoms for a minimum of six months with clinical and radiological features accompanied by at least one of the following:
  • the presence of a sinus
  • the presence of an abscess or intra-operative pus
  • the presence of positive supportive histology
  • two or more microbiological cultures with indistinguishable organisms (defined as cultures resulting in identification of the same microbe (e.g., Staph aureus) with similar antimicrobial sensitivity) Notes: In cases where cultures are negative, a patient will be included in the study only if there is positive supportive histology combined with the presence of a draining sinus or intra-operative pus. Infected non-unions will be included only if the bone loss is < 1cm after debridement and excision of bone has been performed.

Exclusion criteria

The subject will be excluded from the study if:

  • Skeletal immaturity, defined as pre-operative/ screening radiology with evidence of incompletely fused physes. (determined by their previous x-rays which are taken as part of their admission, unrelated to the study)
  • Those unable to give informed consent for inclusion in the trial, or those not willing to be included
  • A known allergy or reaction to gentamicin or calcium sulfate
  • Treatment with a combination of different antibiotic-eluting bone graft substitutes
  • They have a segmental bone defect > 1cm
  • Infection of the spine

Treatment and study plan

CERAMENT G

Device

CERAMENT G is intended for use as a bone void filler as an adjunct to systemic antibiotic therapy and surgical debridement (standard treatment approach to a bone infection) as part of the surgical treatment of osteomyelitis. By eluting gentamicin, CERAMENT G can reduce the recurrence of chronic osteomyelitis from gentamicin-sensitive microorganisms in order to protect bone healing.

Primary outcomes

  1. Composite Endpoint

    Time frame: 36 months

    Overall subject success requires all four of the following at 36 months post-op:

    • absence of a reinfection of the original site of osteomyelitis;
    • absence of purulent drainage and wound dehiscence/breakdown
    • absence of a secondary surgical intervention, e.g., grafting or removal of residual CERAMENT G at the original site; and,
    • a lack of serious adverse events associated with incomplete new bone formation, including pathologic fracture of the treated limb
  2. Co-Primary Endpoint

    Time frame: 36 months

    A trend showing increasing new bone formation and decreasing CERAMENT G as determined by a comparison of baseline and interim post-operative timepoint radiographic evaluations out to 36 months post-operative

Secondary outcomes

  1. Radiographic Succcess

    Time frame: 36 months

    Radiographic success at 36 months, defined as CERAMENT G resorption and new bone formation (a minimum of mean void-filling of 74% in the subject population) as determined by comparison of the immediate post-op radiographs to those at 36 months

  2. Clinical Success

    Time frame: 36 months

    Clinical success at 36 months, defined as:

    Maintenance or improvement in function (i.e., no decrease of PRO(s) in the SF-12 score between post-operative and 36 months follow-up)

Sponsors and collaborators

Lead sponsor

BONESUPPORT AB

Industry

Registry information

Official study title

A Post-Market Prospective Cohort Study on Subjects Receiving CERAMENT G as Part of the Surgical Treatment of Osteomyelitis in a Single-Stage Procedure

Acronym: CERTITUDE

Important dates

Study start
2025
Primary completion
2031
Study completion
2032
First posted
Aug 15, 2024
Registry last updated
May 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.